Neuromyelitis Optica Spectrum Disorders clinical trials at UCSF
1 research study open to eligible people
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
open to eligible people ages 2-17
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
San Francisco, California and other locations
Our lead scientists for Neuromyelitis Optica Spectrum Disorders research studies include Emmanuelle Waubant.